Conclusion of non-exclusive discount agreements pursuant to §§ 130a para. 8/130c para. 1 SGB V for medicinal products containing the active ingredient ertugliflozin (A10BK04) within the framework of a so-called open-house model.
Abschluss nicht exklusiver Rabattverträge gemäß §§ 130a Abs. 8/130c Abs. 1 SGB V zu Arzneimitteln mit dem Wirkstoff Ertugliflozin (A10BK04) im Rahmen eines sogenannten Open-House-Modells.
Germany
Contract
BuyerAOK Rheinland-Pfalz/Saarland - Die Gesundheitskasse
TypeSupplies
Estimated valuevalue not published
Published11 October 2024
CategoryMedical equipment & pharma · CPV 33000000
Who has won here before
| Company | Awards | Period |
|---|---|---|
| axicorp Pharma B.V. · EC Den Haag | 32 | 2017–2022 |
| Aliud Pharma GmbH · Laichingen | 28 | 2017–2023 |
| Abacus Medicine A/S · Kopenhagen | 27 | 2018–2023 |
| kohlpharma GmbH · Merzig | 26 | 2017–2023 |
| EurimPharm Arzneimittel GmbH · Saaldorf-Surheim | 25 | 2019–2023 |
From 13.7M documented awards · regular winners know this buyer's requirements — that is your competition.
How often this buyer tenders this
2019358
2020364
2021382
2022407
2023494
2024460
2025742
2026360
Who knows the rhythm prepares instead of reacting.
42
days until the deadline — Wednesday 30 September at 19:59
How to bid
Read the full notice — Original + documents
Goes directly to this tender on Vergabemarktplatz (cosinex). The full specification and all annexes are there.
Tenders like this, every morning at 7:30 in your inbox.
Start free →